| __timestamp | Alkermes plc | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 45967000 |
| Thursday, January 1, 2015 | 4019000 | 114737000 |
| Friday, January 1, 2016 | 2301000 | 183204000 |
| Sunday, January 1, 2017 | 7232000 | 231644000 |
| Monday, January 1, 2018 | 68895000 | 293998000 |
| Tuesday, January 1, 2019 | 52816000 | 357355000 |
| Wednesday, January 1, 2020 | 1946000 | 412084000 |
| Friday, January 1, 2021 | 1020000 | 497153000 |
| Saturday, January 1, 2022 | 393842000 | 705789000 |
| Sunday, January 1, 2023 | 270806000 | 648449000 |
| Monday, January 1, 2024 | 245326000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alkermes plc and Ultragenyx Pharmaceutical Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Ultragenyx's R&D expenses surged by over 1,300%, peaking at approximately $706 million in 2022. This aggressive investment reflects their focus on pioneering treatments for rare and ultra-rare diseases. In contrast, Alkermes showed a more fluctuating pattern, with a significant spike in 2022, reaching nearly $394 million, a 5,000% increase from their 2014 spending.
These trends highlight the dynamic nature of R&D strategies in the biopharma sector, where companies must balance innovation with financial sustainability. As the industry evolves, monitoring these investments offers valuable insights into future breakthroughs and market leadership.
Eli Lilly and Company or Alkermes plc: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for argenx SE and Ultragenyx Pharmaceutical Inc.
Research and Development: Comparing Key Metrics for BeiGene, Ltd. and Alkermes plc
Research and Development Investment: Summit Therapeutics Inc. vs Alkermes plc
R&D Insights: How Jazz Pharmaceuticals plc and Ultragenyx Pharmaceutical Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Blueprint Medicines Corporation and Alkermes plc
R&D Spending Showdown: Blueprint Medicines Corporation vs Ultragenyx Pharmaceutical Inc.
Alkermes plc vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Amneal Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Vericel Corporation
Research and Development Expenses Breakdown: Ultragenyx Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Xencor, Inc.